Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BBIO – BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc.
BBIO
$47.37
Name : BridgeBio Pharma, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $8,994,662,400.00
EPSttm : -3.56
finviz dynamic chart for BBIO
BridgeBio Pharma, Inc.
$47.37
0.21%
$0.1

Float Short %

12.11

Margin Of Safety %

Put/Call OI Ratio

0.5

EPS Next Q Diff

0.22

EPS Last/This Y

0.28

EPS This/Next Y

0.91

Price

47.37

Target Price

62.57

Analyst Recom

1.23

Performance Q

23.36

Relative Volume

0.77

Beta

1.23

Ticker: BBIO




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04BBIO43.990.510.7175682
2025-07-07BBIO43.490.510.3176106
2025-07-08BBIO43.190.510.4476235
2025-07-09BBIO45.990.510.8076451
2025-07-10BBIO46.280.530.2478342
2025-07-11BBIO46.490.540.3778425
2025-07-14BBIO47.720.541.1478587
2025-07-15BBIO46.950.550.1679436
2025-07-16BBIO47.10.550.5079951
2025-07-17BBIO46.750.550.3980062
2025-07-18BBIO46.510.550.1681023
2025-07-21BBIO45.90.440.9964745
2025-07-22BBIO45.760.4527.4165163
2025-07-23BBIO46.170.550.1670295
2025-07-24BBIO45.660.511.1375276
2025-07-25BBIO46.290.520.7677170
2025-07-28BBIO46.240.520.1777390
2025-07-29BBIO46.30.511.3879365
2025-07-30BBIO45.610.510.3979519
2025-07-31BBIO47.240.510.0680136
2025-08-01BBIO47.390.501.1881520
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04BBIO43.9961.0118.5-2.34
2025-07-07BBIO43.4961.0132.8-2.34
2025-07-08BBIO43.1961.0131.2-2.34
2025-07-09BBIO45.9861.0104.6-2.34
2025-07-10BBIO46.2761.0126.2-2.34
2025-07-11BBIO46.4761.0124.5-2.34
2025-07-14BBIO47.9061.0117.0-2.34
2025-07-15BBIO46.9761.0134.2-2.34
2025-07-16BBIO47.0961.0127.5-2.34
2025-07-17BBIO46.7461.0131.4-2.34
2025-07-18BBIO46.5361.0130.2-2.34
2025-07-21BBIO45.9061.0133.4-2.34
2025-07-22BBIO45.7861.0129.4-2.34
2025-07-23BBIO46.1961.0125.1-2.34
2025-07-24BBIO45.6658.3132.8-2.47
2025-07-25BBIO46.3058.3123.3-2.47
2025-07-28BBIO46.1639.9129.6-2.60
2025-07-29BBIO46.3239.9127.8-2.60
2025-07-30BBIO45.6239.9134.0-2.60
2025-07-31BBIO47.2739.9115.0-2.60
2025-08-01BBIO47.3739.9127.8-2.60
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04BBIO-40.664.9113.14
2025-07-07BBIO-40.664.8813.13
2025-07-08BBIO-40.744.8813.13
2025-07-09BBIO-40.744.8813.13
2025-07-10BBIO-40.744.8813.13
2025-07-11BBIO-40.744.8813.57
2025-07-14BBIO-40.744.6913.57
2025-07-15BBIO-40.744.6913.57
2025-07-16BBIO-40.744.6913.57
2025-07-17BBIO-40.744.6913.57
2025-07-18BBIO-40.744.6913.57
2025-07-21BBIO-40.743.2813.57
2025-07-22BBIO-40.743.2813.57
2025-07-23BBIO-40.743.2813.57
2025-07-24BBIO-40.743.2813.57
2025-07-25BBIO-40.743.2812.11
2025-07-28BBIO-40.743.1912.11
2025-07-29BBIO-40.743.1912.11
2025-07-30BBIO-40.743.1912.11
2025-07-31BBIO-39.923.1912.11
2025-08-01BBIO-35.853.1912.11
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.88

Avg. EPS Est. Current Quarter

-0.39

Avg. EPS Est. Next Quarter

-0.66

Insider Transactions

-35.85

Institutional Transactions

3.19

Beta

1.23

Average Sales Estimate Current Quarter

101

Average Sales Estimate Next Quarter

117

Fair Value

Quality Score

24

Growth Score

41

Sentiment Score

88

Actual DrawDown %

35.6

Max Drawdown 5-Year %

-92.8

Target Price

62.57

P/E

Forward P/E

PEG

P/S

70.59

P/B

P/Free Cash Flow

EPS

-3.53

Average EPS Est. Cur. Y​

-2.6

EPS Next Y. (Est.)

-1.69

Target Price Estimates Raised

1

Target Price Estimates Lowered

Profit Margin

-524.25

Relative Volume

0.77

Return on Equity vs Sector %

16.8

Return on Equity vs Industry %

35.4

EPS 1 7Days Diff

-0.4

EPS 1 30Days Diff

-0.26

EBIT Estimation

127.8
BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 725
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
stock quote shares BBIO – BridgeBio Pharma, Inc. Stock Price stock today
news today BBIO – BridgeBio Pharma, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch BBIO – BridgeBio Pharma, Inc. yahoo finance google finance
stock history BBIO – BridgeBio Pharma, Inc. invest stock market
stock prices BBIO premarket after hours
ticker BBIO fair value insiders trading